---
layout: default
title: Vaborbactam
parent: Model Prediction Only (L5)
nav_order: 815
evidence_level: L5
indication_count: 10
---

# Vaborbactam
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **10** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

# Vaborbactam: From Unknown Original Indication to Osteoarthritis

## One-Sentence Summary

Vaborbactam is a boronic acid–based β-lactamase inhibitor; detailed original indication and mechanism-of-action data are not available in the current evidence pack.
The TxGNN model predicts it may be effective for **Osteoarthritis**,
but currently **no clinical trials** and **no publications** support this direction — the prediction is based on model inference alone.

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not recorded in evidence pack (no `original_indications` or Canada license text available) |
| Predicted New Indication | Osteoarthritis |
| TxGNN Prediction Score | 98.52% |
| Evidence Level | L5 |
| Canada Market Status | Not Marketed |
| Number of DINs | 0 |
| Recommended Decision | Hold |

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available. Based on known information, vaborbactam is a boronic-acid class β-lactamase inhibitor that is not administered alone — it is used as a combination-product component alongside meropenem (marketed internationally as Vabomere) to restore antibacterial activity against carbapenem-resistant Enterobacterales, primarily for complicated urinary tract infections. Its efficacy in this context is well established, but this evidence pack does not confirm whether vaborbactam is marketed in Canada or under what indication.

There is no known pharmacological pathway connecting a β-lactamase inhibitor to osteoarthritis pathophysiology, which involves cartilage degradation, subchondral bone remodeling, and low-grade joint inflammation (e.g., IL-1β, MMP, prostaglandin pathways). Vaborbactam has no documented anti-inflammatory, chondroprotective, or immunomodulatory activity.

The TxGNN score of 98.52% likely reflects an indirect knowledge-graph path (e.g., shared protein or pathway nodes) rather than a validated biological mechanism. The `repurposing_rationale.mechanistic_link` field in the evidence pack explicitly notes this is an unvalidated, high-score prediction with no supporting hypothesis — consistent with the L5 evidence level and S0 decision stage.

## Clinical Trial Evidence

Currently no related clinical trials registered

## Literature Evidence

Currently no related literature available

## Canada Market Information

No Canada market authorization records are currently available for vaborbactam (0 licenses on file; market status: Not Marketed).

## Safety Considerations

Please refer to the package insert for safety information.

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The prediction is supported only by a TxGNN model score (Evidence Level L5, Decision Stage S0) with zero clinical trials or literature, and there is no plausible mechanistic link between a β-lactamase inhibitor and osteoarthritis pathophysiology. A blocking data gap also exists for TFDA/label safety information, which by itself prevents progression to safety pre-assessment (S1).

**To proceed, the following is needed:**
- Confirmed mechanism of action (MOA) data from DrugBank or primary literature
- Product label warnings and contraindications (currently blocking gap, DG001)
- At minimum preclinical or mechanistic evidence linking vaborbactam to joint/cartilage pathways before considering further investment
- Confirmation of Canada market/regulatory status, since none is currently on file
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

